Increased expression of osteopontin in patients with triple-negative breast cancer

European Journal of Clinical Investigation

Volumn 38, Issue 6, 2008, Pages 438-446

  Wang, X ^a   Chao, L ^a   Ma, G ^a   Chen, L ^a   Tian, B ^a   Zang, Y ^a   Sun, J ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Breast cancer; Gene; Osteopontin; Triple negative phenotype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; OSTEOPONTIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; OSTEOPONTIN; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 44049093342     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01956.x     Document Type: Article

References (31)

1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast cancers subtype, and survival in the Carolina breast cancer study. JAMA 2006 295 : 2492 502.
2. Sorlie T, Perou CM, Tibshirani R, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003 100 : 8418 23.
3. Brenton JD, Catry LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005 23 : 7350 60.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 10 : 5367 74.
5. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al. Phenotype evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006 19 : 264 71.
6. Matos I, Dufloth R, Alwarenga M, Zeferino LC, Schmitt F. P63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005 447 : 688 94.
7. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N et al. Germline BRCA1 mutation and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003 95 : 1482 5.
8. Rangaswami H, Bulbule A, Kundu GC, Ahmed M, Sharma P, Kumar V et al. Ostropnontin: role in cell signaling and cancer progression. Trends Cell Biol 2006 16 : 79 87.
9. Chakerborty G, Jain S, Behera R, Aluned M, Sharma P, Kumar V et al. The multifaceted role of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006 6 : 819 30.
10. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006 94 : 325 31.
11. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002 62 : 3417 27.
12. Tuck AB, Hota C, Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001 70 : 197 204.
13. Alison AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006 169 : 233 46.
14. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, £ Brunet M et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989 64 : 1914 21.
15. Greene FI. Page DI, Fleming ID. AJCC Cancer Staging Manual, 6th edn. New York : Springer 2002.
16. Peter EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN et al. HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002 77 : 148 54.
17. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997 121 : 578 84.
18. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998 79 : 502 8.
19. Jimenez RE, Wallis T, Visscher DW. Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior. Am J Surg Pathol 2001 25 : 331 7.
20. Jones C, Nonni AV, Fulford I, Merrett S, Chaggar R, Eusebbi V et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001 85 : 422 7.
21. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007 9 : R65.
22. Rakha EA, Tan DSP, Foulkes WD, Ellis IO, Tutt A, Nielsen TO et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 2007 13 : R80.
23. Kreike B, van de Vijver MJ. Are triple-negative tumours and basal-like breast cancer synonymous? Author's response. Breast Cancer Res 2007 9 : 405.
24. Haffty BG, Yang QF, Reiss M, Kearney T, Higgins SA, Weidhaas J et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006 24 : 5652 7.
25. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001 345 : 1378 87.
26. Singhal H, Bautista DS, Tonkin KSO, Malley FP, Tuck AB, Chambers AF et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997 3 : 605 11.
27. Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 2007 171 : 682 92.
28. Martinetti A, Bajetta E, Ferrari L, Zilembo N, Seregni E et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004 11 : 771 9.
29. Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH et al. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation. Mol Cancer 2007 16 : 6.
30. Cook AC, Chambers AF, Turley EA, Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006 281 : 24381 9.
31. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC et al. Osteopontin induces multiple changes in gene expression that reflect the six 'hallmarks of cancer' in a model of breast cancer progression. Mol Carcinog 2005 43 : 225 36.